High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Malignant solid tumors
• Must have failed conventional treatment or for whom conventional therapy is not available
• Measurable disease by MRI or CT scan
• * Intraocular retinoblastomas may be measured by direct visualization
• * Germ cell tumors may be measured by tumor markers
• No known bone marrow involvement
• PATIENT CHARACTERISTICS:
• Age:
• Any age
• Performance status:
• Lansky 60-100% for patients 16 and under
• Karnofsky 60-100% for patients over 16
• Life expectancy:
• At least 8 weeks
• Hematopoietic:
• Absolute neutrophil count at least 1,000/mm\^3
• Platelet count at least 75,000/mm\^3
• If parameters not met, must have adequate stem cell yield
• Hepatic:
• Bilirubin no greater than 1.5 times the upper limit of normal (ULN)
• SGOT and SGPT no greater than 2.5 times the ULN (unless liver involvement by tumor)
• Renal:
• Creatinine within normal limits OR
• Creatinine clearance at least 70 mL/min
• Cardiovascular:
• Fractional shortening greater than 28% on echocardiogram OR
• Ejection fraction at least 55% on RNCA prior to first cycle of thiotepa
• Pulmonary:
• DLCO greater than 55% of predicted (only required if there is clinical evidence of pulmonary dysfunction)
• Other:
• Not pregnant or nursing
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Prior bone marrow or peripheral blood stem cell rescue allowed
• Chemotherapy:
• At least 4 weeks since prior chemotherapy if absolute neutrophil count is less than 1,000/mm\^3 or platelet count is less than 75,000/mm\^3, and recovered (i.e. adequate stem cells collected to predict hematopoietic recovery)
• No concurrent chemotherapy except for dexamethasone for antiedema effects
• Endocrine therapy:
• No concurrent use of corticosteroids used solely as antiemetics
• Radiotherapy:
• At least 4 weeks since radiotherapy if absolute neutrophil count is less than 1,000/mm\^3 or platelet count is less than 75,000/mm\^3, and recovered (i.e. adequate stem cells collected to predict hematopoietic recovery)
• No concurrent radiotherapy
• Surgery:
• Not specified